Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Multiple Sclerosis is a disease that affects the brain and the central nervous system. Twenty years ago there were no therapies to treat MS, whereas eight drugs have been registered today. Professor Fugger tries to understand in detail how various genes confer risk to MS, and translate genetic findings into a clinical setting.

Q: What is multiple sclerosis and what causes it?

LF: Multiple Sclerosis (MS) is a disease that affects the brain and the central nervous system. It's a disease where the immune system all of a sudden instead of attacking invading viruses and bacteria go wrong and start to attack the brain and central nervous system. It's a so-called auto-immune disease. It's unknown today what's causing multiple sclerosis; it's a combination of genetic factors, genes we're getting from our parents and unknown environmental factors.

Q: Can you give us examples of these environmental factors?

LF: It has been discussed for many years which factors in our environment could cause or trigger MS. So we should be careful when we talk about a single factor causing multiple sclerosis. We will have a combination of factors from our genes and from the environment. It has been speculated that Epstein-Barr virus is a triggering factor and there's evidence to suggest this but it's a minor risk factor. Apart from that very few other environmental factors have been identified so far.

Q: Can your research help us to design better treatments?

LF: Our research is trying to take advantage of the genetic revolution that is taking place in real time, right now. So we are exploiting the newly identified genes to understand how they confirm risk, how they predispose to multiple sclerosis. And we are trying to translate that knowledge into a clinical setting.

Q: What are the most important lines of research that have developed over the past 5-10 years?

LF: Clearly twenty years ago we had no therapy we could treat the MS patients with. Today we have eight drugs that have been registered to treat patients with MS. This has all come out of various research programmes. You can't pinpoint a single research programme but you could say that they have all been coming together to show how MS can be treated. What we can treat today is the immune system that simply has gone wrong. We can keep that immune system at bay.

Q: Why does your line of research matter? Why should we put money into it?

LF: Our research is different from many other groups' research in the MS field because we are trying to understand in detail how various genes confer risk to MS. So we are trying to translate genetic findings into a clinical setting. We are trying to understand how you can shine light on mechanisms in MS and how that can be translated into new therapies.

Q: How does your research fit into Translational Medicine within the department?

LF: Our research is fitting quite well into a translational approach within the department as we have already demonstrated how we can translate findings in the lab into a clinical setting. So we have reasonably been showing that a drug that was discovered in our lab also has efficacy. It has a good effect in MS patients. So it's a good example of how you can go from the lab to the bedside and translate basic findings into a clinical, meaningful context.

Professor Lars Fugger

Researching Multiple Sclerosis

Professor Lars Fugger focuses on translational studies in multiple sclerosis and uses a multidisciplinary approach. He is seeking to understand the molecular basis for the MHC association in MS and how MHC genes interact with environmental factors such as viruses. Professor Fugger's group consists of both basic scientists and clinicians.

This podcast presents the research done by Professor Fugger whilst working in the Nuffield Department of Medicine. Professor Lars Fugger now works at the Nuffield Department of Clinical Neurosciences.

More podcasts related to Ex-faculty podcasts

Raghib Ali: INDOX Cancer Research Network

INDOX is a collaboration between Oxford and twelve leading cancer centres in India. It aims to develop effective and affordable cancer treatments in low and middle income countries, to improve the early detection of cancer, and to reduce the incidence of cancer by establishing the population specific risk factors.

Richard Antrobus: Universal Flu Vaccine

A Universal Flu Vaccine would protect against a wide range of strains of the virus. Universal vaccines target the parts of the virus that stay relatively stable and are the same between different strains of flu. The ultimate goal is to produce a vaccine that will eventually replace the normal seasonal flu jab.

Colin Baigent: Lowering cholesterol in chronic kidney disease

The SHARP study involved almost 9,500 volunteers aged 40 or over with chronic kidney disease recruited from 380 hospitals in 18 countries. Volunteers were randomly allocated to take either cholesterol-lowering therapy with a tablet containing ezetimibe 10mg daily and simvastatin 20mg daily, or matching dummy "placebo" tablets for an average of 5 years.

Colin Baigent: Wider statin use saves lives

Prof Colin Baigent discusses how the benefits outweigh the hazards of Cholesterol-lowering drugs.

Paul Bowness: Spondyloarthritis

Spondyloarthritis describes a group of arthritic illnesses where there is inflammation of the joints of the lower back. Joints become painful and stiff, and inflammation ultimately fuses the spine. A better understanding of the role of various immune components might help us better prevent it and perhaps cure it.

Vincenzo Cerundolo: Cancer immunology

The development of therapeutic vaccines is more challenging. Current lines of research include the development of antibodies blocking inhibitory T cell signals, and the characterisation of adjuvants.

Hal Drakesmith: Iron and Infection

Pathogens can escape recognition by the immune system, but they require iron from their host to grow and spread. If iron availability is high, infection can progress more rapidly. Diverting iron away from invading microbes slows their growth, giving time for our immune mechanisms to clear the infection. Manipulating iron transport might lead to new strategies to combat infections.

Christian Eggeling: Nano-immunology

Super-resolution optical microscopy allows us to study immunological processes on the molecular level. We can get new insights into how our body reacts to viral or bacterial attacks. This has the potential to help us design new drugs and developing new ways of treating diseases.

Barbara Fielding: Metabolism of Fatty Acids

Obesity puts a huge strain on health care services in the UK, with 61% of people in England being overweight. By tracing fats containing heavy atoms from meals into the blood, her aim is to learn more about fat metabolism and target treatments for the complications associated with obesity and diabetes.

Alexander Finlayson: MedicineAfrica

This podcast presents the research done by Dr Alexander Finlayson whilst working in the Nuffield Department of Medicine. Dr Finlayson now works at the Nuffield Department of Population Health.

Translational Medicine

From Bench to Bedside

Ultimately, medical research must translate into improved treatments for patients. At the Nuffield Department of Medicine, our researchers collaborate to develop better health care, improved quality of life, and enhanced preventative measures for all patients. Our findings in the laboratory are translated into changes in clinical practice, from bench to bedside.